Myelodysplastic Syndromes and Myeloproliferative Neoplasms New Findings in Hematology: Independent Conference Coverage of Hematology 2016

December 3-6, 2016; San Diego, California
In this Expert Analysis, Jamile Shammo, MD, FASCP, FACP, and Rami S. Komrokji, MD, discuss the clinical applicability of new, key findings in myelodysplastic syndromes and myeloproliferative neoplasms presented at Hematology 2016.
Rami S. Komrokji, MD
Jamile Shammo, MD, FASCP, FACP
Released: January 24, 2017 Expiration: No longer available for credit

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with myelodysplastic syndromes and/or myeloproliferative neoplasms
  • Identify subpopulations of patients with myelodysplastic syndromes and/or myeloproliferative neoplasms most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss the unique mechanisms of action of promising investigational agents being studied for the treatment of myelodysplastic syndromes and/or myeloproliferative neoplasms
  • Evaluate emerging clinical data on novel agents and therapeutic strategies that have the potential to improve the outcomes for patients with myelodysplastic syndromes and/or myeloproliferative neoplasms

Acknowledgements

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of South Florida
Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Rami S. Komrokji, MD, has disclosed that he has received consulting fees from Celgene, Incyte, and Novartis; fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Novartis; and funds for research support from Celgene.
Jamile Shammo, MD, FASCP, FACP

Professor of Medicine and Pathology
Division of Hematology, Oncology, and Stem Cell Transplant
Director, MDS/MPN/Aplastic Anemia Program 
Rush University Medical Center
Chicago, Illinois

Jamile Shammo, MD, FASCP, FACP, has disclosed that she has received consulting fees, fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus), and funds for research support from Alexion, Celgene, Incyte, and Novartis.

Staff

Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, Debbie Price, Registration Database Administrator, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers involved in caring for patients with myelodysplastic syndromes and/or myeloproliferative neoplasms.

Goal

The goal of this activity is to improve participants’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with myelodysplastic syndromes and/or myeloproliferative neoplasms.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 24, 2017, through January 23, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Download this slideset to review the latest clinical data informing optimal management strategies for follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

Download this ExpressPoints slideset for a quick summary of the latest clinical data informing optimal management of follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

In this slideset from Clinical Care Options (CCO), experts review treatment options after BTK inhibitor– and venetoclax for patients with CLL.

Jeremy S. Abramson, MD, MMSc Released: October 14, 2020

Expert insight commentary from Clinical Care Options (CCO) on use of luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) patients

Guillermo Garcia-Manero, MD Released: October 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue